Results from a U.S. trial of AstraZeneca's COVID-19 vaccine may have used "outdated information," U.S. federal health officials said in a statement early Tuesday.
Late Monday, the Data and Safety Monitoring Board said in a statement that it was concerned that AstraZeneca may have provided an incomplete view of the efficacy data.
Late Monday, the Data and Safety Monitoring Board said in a statement that it was concerned that AstraZeneca the included outdated information from that trial may have provided an incomplete view of the efficacy data.
AstraZeneca reported Monday that its COVID-19 vaccine provided strong protection among adults of all ages in a long-anticipated U.S.